



Arbutus to Participate in Upcoming Investor Conferences

October 10, 2017

VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company will be participating in the following investor conferences:

- Chardan Inaugural Gene Therapy Conference, October 10, 2017, New York, and
- Jefferies Gene Technology Summit, October 12, 2017, New York.

About Arbutus

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.

Contact Information

Investors

Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604-419-3200
Email: acutler@arbutusbio.com

Tiffany Tolmie
Manager, Investor Relations
Phone: 604-419-3200
Email: ttolmie@arbutusbio.com

Media

David Schull
Russo Partners
Phone: 858-717-2310
Email: david.schull@russopartnersllc.com

Primary Logo

Source: Arbutus Biopharma Corporation